Gene · 2073
Papers2,901
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 2,901
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Correlation of ERCC5 polymorphisms and linkage disequilibrium associated with overall survival and clinical outcome to chemotherapy in breast cancer. | Front Oncol | 2022 | 36686735 | PubTator, text mining | PubMed |
| Gene polymorphisms and risk of head and neck squamous cell carcinoma: a systematic review. | Rep Pract Oncol Radiother | 2022 | 36632298 | PubTator, text mining | PubMed |
| Gene polymorphisms and prognosis of head and neck squamous cell carcinoma: a systematic review. | Rep Pract Oncol Radiother | 2022 | 36632296 | PubTator, text mining | PubMed |
| Next-Generation Sequencing in the Assessment of the Transcriptomic Landscape of DNA Damage Repair Genes in Abdominal Aortic Aneurysm, Chronic Venous Disease and Lower Extremity Artery Disease. | Int J Mol Sci | 2022 | 36614026 | PubTator, text mining | PubMed |
| Exonuclease 1 genetic variant is associated with clinical outcomes of pemetrexed chemotherapy in lung adenocarcinoma. | J Cancer | 2022 | 36606188 | PubTator, text mining | PubMed |
| Verrucous Carcinoma of Tongue in Xeroderma Pigmentosum: A Case Report and Literature Review. | Cureus | 2022 | 36561591 | PubTator, text mining | PubMed |
| Targeting the DNA Damage Response Machinery for Lung Cancer Treatment. | Pharmaceuticals (Basel) | 2022 | 36558926 | PubTator, text mining | PubMed |
| Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients. | Int J Mol Sci | 2022 | 36555431 | PubTator, text mining | PubMed |
| Pathologic Findings at Risk Reducing Surgery in BRCA and Non-BRCA Mutation Carriers: A Single-Center Experience. | Diagnostics (Basel) | 2022 | 36553061 | PubTator, text mining | PubMed |
| AP-2δ Is the Most Relevant Target of AP-2 Family-Focused Cancer Therapy and Affects Genome Organization. | Cells | 2022 | 36552887 | PubTator, text mining | PubMed |
| Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets. | Cancers (Basel) | 2022 | 36551731 | PubTator, text mining | PubMed |
| Cancer and Radiosensitivity Syndromes: Is Impaired Nuclear ATM Kinase Activity the Primum Movens? | Cancers (Basel) | 2022 | 36551628 | PubTator, text mining | PubMed |
| Xanthogranulomatous pyelonephritis: Case series - Clinical, radiologic, therapeutic, and histological aspects. | Urol Ann | 2022 | 36505992 | PubTator, text mining | PubMed |
| Revisiting the Anti-Cancer Toxicity of Clinically Approved Platinating Derivatives. | Int J Mol Sci | 2022 | 36499737 | PubTator, text mining | PubMed |
| Immunological and Genomic Analysis Reveals Clinically Relevant Distinctions between Angiosarcoma Subgroups. | Cancers (Basel) | 2022 | 36497420 | PubTator, text mining | PubMed |
| The XPA Protein-Life under Precise Control. | Cells | 2022 | 36496984 | PubTator, text mining | PubMed |
| NEDDylated Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors. | Sci Adv | 2022 | 36490343 | PubTator, text mining | PubMed |
| Cellular and molecular effects of PNCK, a non-canonical kinase target in renal cell carcinoma. | iScience | 2022 | 36465101 | PubTator, text mining | PubMed |
| Insufficient Dose of ERCC8 Protein Caused by a Frameshift Mutation Is Associated With Keratoconus With Congenital Cataracts. | Invest Ophthalmol Vis Sci | 2022 | 36454558 | PubTator, text mining | PubMed |
| Germline Variants in DNA Damage Repair Genes and HOXB13 Among Black Patients With Early-Onset Prostate Cancer. | JCO Precis Oncol | 2022 | 36446039 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2073/papers?page=15